Fear of new or recurrent melanoma after treatment for localised melanoma

Psycho-Oncology

Volumn 26, Issue 11, 2017, Pages 1784-1791

  Bell, Katy J L ^a,b   Mehta, Yachna ^c   Turner, Robin M ^d   Morton, Rachael L ^e   Dieng, Mbathio ^a,f   Saw, Robyn ^c,e,g   Guitera, Pascale ^c,e,g   McCaffery, Kirsten ^a   Low, Donald ^h   Low, Cynthia ^h   Jenkins, Marisa ^a   Irwig, Les ^a   Webster, Angela C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b BOND UNIVERSITY   (Australia)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f MACQUARIE UNIVERSITY   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h Cancer Voices NSW   (Australia)

Author keywords

cancer; fear; melanoma; oncology; recurrence; surveys and questionnaires

Indexed keywords

ADULT; AGED; ARTICLE; FEAR; FEAR OF CANCER RECURRENCE INVENTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PATIENT WORRY; QUESTIONNAIRE; RECURRENCE RISK; SCORING SYSTEM; TUMOR LOCALIZATION; TUMOR RECURRENCE; AUSTRALIA; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PSYCHOLOGY; SKIN TUMOR;

ADULT; AUSTRALIA; FEAR; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SKIN NEOPLASMS; SURVEYS AND QUESTIONNAIRES;

EID: 85011659715     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.4366     Document Type: Article

References (31)

1. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27:3–9.
2. Levell NJ, Beattie CC, Shuster S, Greenberg DC. Melanoma epidemic: a midsummer nights dream? Br J Dermatol. 2009;161:630–634.
3. Coory M, Baade P, Aitken J, Smithers M, McLeod GR, Ring I. Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002. Cancer Causes Control. 2006;17:21–27.
4. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ. 2005;331:481
5. Youlden DR, Youl PH, Soyer H, Aitken JF, Baade PD. Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma in Queensland, Australia, 1982-2010. JAMA Dermatol. 2014;150:526–534.
6. van der Leest RJ, Flohil SC, Arends LR, de Vries E, Nijsten T. Risk of subsequent cutaneous malignancy in patients with prior melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol. 2015;29:1053–1062.
7. Australia Cancer Network & New Zealand Guidelines Group. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. 2008. Available from: http://www.nhmrc.gov.au/publications/synopses/cp111syn.htm. Accessed April 2016.
8. Mocellin S, Nitti D. Cutaneous melanoma in situ: translational evidence from a large population-based study. Oncologist. 2011;16:896–903.
9. Green AC, Baade P, Coory M, Aitken JF, Smithers M. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol. 2012;30:1462–1467.
10. Molassiotis A, Brunton L, Hodgetts J, et al. Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. Ann Oncol. 2014;25:2052–2058.
11. McLoone J, Watts K, Menzies S, Meiser B, Butow P, Kasparian N. When the risks are high: psychological adjustment among melanoma survivors at high risk of developing new primary disease. Qual Health Res. 2012;22:1102–1113.
12. Morton RL, Rychetnik L, McCaffery K, Thompson JF, Irwig L. Patients perspectives of long-term follow-up for localised cutaneous melanoma. Eur J Surg Oncol. 2013;39:297–303.
13. van de Wal M, van de Poll-Franse L, Prins J, Gielissen M. Does fear of cancer recurrence differ between cancer types? A study from the population-based PROFILES registry. Psychooncology. 2016;25:772–778.
14. Lebel S, Ozakinci G, Humphris G, et al. From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. Support Care Cancer. 2016;24:3265–3268.
15. Baker F, Denniston M, Smith T, West MM. Adult cancer survivors: how are they faring? Cancer. 2005;104(11 Suppl):2565–2576.
16. Simard S, Thewes B, Humphris G, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv. 2013;7:300–322.
17. Simard S, Savard J. Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer. 2009;17:241–251.
18. Beesley VL, Smithers BM, O'Rourke P, Janda M, Khosrotehrani K, Green AC. Variations in supportive care needs of patients after diagnosis of localised cutaneous melanoma: a 2-year follow-up study. Support Care Cancer. 2016;1–10. Published ahead of print Aug 25. doi: 10.1007/s00520-016-3378-9
19. Beesley VL, Smithers BM, Khosrotehrani K, et al. Supportive care needs, anxiety, depression and quality of life amongst newly diagnosed patients with localised invasive cutaneous melanoma in Queensland, Australia. Psychooncology. 2015;24:763–770.
20. Kasparian NA, McLoone JK, Butow PN. Psychological responses and coping strategies among patients with malignant melanoma: a systematic review of the literature. Arch Dermatol. 2009;145:1415–1427.
21. Simard S, Savard J. Screening and comorbidity of clinical levels of fear of cancer recurrence. J Cancer Surviv. 2015;9:481–491.
22. Costa DSJ, Dieng M, Cust AE, Butow PN, Kasparian NA. Psychometric properties of the Fear of Cancer Recurrence Inventory: an item response theory approach. Psychooncology. 2016;25:832–838.
23. Costa DSJ, Smith AB, Fardell JE. The sum of all fears: conceptual challenges with measuring fear of cancer recurrence. Support Care Cancer. 2016;24:1–3.
24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Text revision. 4th ed. Washington: American Psychiatric Association; 2000.
25. Mutsaers B, Jones G, Rutkowski N, et al. When fear of cancer recurrence becomes a clinical issue: a qualitative analysis of features associated with clinical fear of cancer recurrence. Support Care Cancer. 2016;24:4207–4218.
26. Lebel S, Simard S, Harris C, et al. Empirical validation of the English version of the Fear of Cancer Recurrence Inventory. Qual Life Res. 2016;25:311–321.
27. Damude S, Hoekstra-Weebers JE, Francken AB, Ter Meulen S, Bastiaannet E, Hoekstra HJ. The MELFO-study: prospective, randomized, clinical trial for the evaluation of a stage-adjusted reduced follow-up schedule in cutaneous melanoma patients-results after 1 year. Ann Surg Oncol. 2016;23:2762–2771.
28. Coups EJ, Manne SL, Stapleton JL, Tatum KL, Goydos JS. Skin self-examination behaviors among individuals diagnosed with melanoma. Melanoma Res. 2016;26:71–76.
29. Bird J, Coleman P, Danson S. Coping with melanoma-related worry: a qualitative study of the experiences and support needs of patients with malignant melanoma. J Clin Nurs. 2015;24:937–947.
30. Zschocke I, Grimme H, Muthny FA. Self-examination of patients with malignant melanoma in the aftercare: relevance of psychosocial factors and instructions by the physicians. Dermatol Psychosom. 2000;1(Suppl. 1):8–14.
31. Dieng M, Butow PN, Costa DSJ, et al. Psychoeducational intervention to reduce fear of cancer recurrence in people at high risk of developing another primary melanoma: results of a randomized controlled trial. J Clin Oncol. 2016; Published online before print October 10, 2016. doi: 10.1200/JCO.2016.68.2278